Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 40, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13046-020-01788-4
Keywords
Breast cancer; Endocrine therapy; PI3K-AKT-mTOR pathway; CDK4; 6; Tumor immune microenvironment
Categories
Funding
- Natural Science Foundation of Zhejiang Province [LR19H160001]
- Zhejiang Provincial Ministry Co-construction Plan [WKJ-ZJ-1716]
- Zhejiang Public Welfare Technology Research Program [LGF18H160022]
- Natural Science Foundation of China [82073151]
Ask authors/readers for more resources
SERMs and SERDs are standard therapies for ER-positive breast cancer, and they also modulate the immune microenvironment. The immune microenvironment plays a crucial role in tumor development, treatment response, and could potentially enhance the effectiveness of immune checkpoint inhibitors in breast cancer treatment.
Endocrine therapies with SERMs (selective estrogen receptor modulators) or SERDs (selective estrogen receptor downregulators) are standard therapies for patients with estrogen receptor (ER)-positive breast cancer. Multiple small molecule inhibitors targeting the PI3K-AKT-mTOR pathway or CDK4/6 have been developed to be used in combination with anti-estrogen drugs to overcome endocrine resistance. In addition to their direct antitumor effects, accumulating evidence has revealed the tumor immune microenvironment (TIM)-modulating effects of these therapeutic strategies, which have not been properly acknowledged previously. The immune microenvironment of breast tumors plays a crucial role in tumor development, metastasis and treatment response to endocrine therapy and immunotherapy. Therefore, in our current work, we comprehensively review the immunomodulatory effect of endocrine therapy and discuss its potential applications in combination with immune checkpoint inhibitors in breast cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available